<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:e486e01b-df70-4ab7-8d1b-b77184232e77,g:851f5ab7-9f69-4a44-a058-6d65a7fb4811,d:30b70720e7a840089df4218d50729d1e--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>smmt-20220125</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i038cf3deceb14d27bdb232ec39ade856_D20220125-20220125" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjMwYjcwNzIwZTdhODQwMDg5ZGY0MjE4ZDUwNzI5ZDFlL3NlYzozMGI3MDcyMGU3YTg0MDA4OWRmNDIxOGQ1MDcyOWQxZV80L2ZyYWc6ZmMxMjI2NzFhNTJjNDdlZTg2MWFhMTBiOTQ3YTIwZWEvdGFibGU6ODY3ZmY0NzRkNTcxNDYxMGFhYTFjM2MxNDI2NmQ2ZDMvdGFibGVyYW5nZTo4NjdmZjQ3NGQ1NzE0NjEwYWFhMWMzYzE0MjY2ZDZkM18wLTEtMS0xLTQ0Nzk0_44e684f3-0c58-41b5-86d1-cec9347b898a">0001599298</ix:nonNumeric><ix:nonNumeric contextRef="i038cf3deceb14d27bdb232ec39ade856_D20220125-20220125" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjMwYjcwNzIwZTdhODQwMDg5ZGY0MjE4ZDUwNzI5ZDFlL3NlYzozMGI3MDcyMGU3YTg0MDA4OWRmNDIxOGQ1MDcyOWQxZV80L2ZyYWc6ZmMxMjI2NzFhNTJjNDdlZTg2MWFhMTBiOTQ3YTIwZWEvdGFibGU6ODY3ZmY0NzRkNTcxNDYxMGFhYTFjM2MxNDI2NmQ2ZDMvdGFibGVyYW5nZTo4NjdmZjQ3NGQ1NzE0NjEwYWFhMWMzYzE0MjY2ZDZkM18xLTEtMS0xLTQ0Nzk0_53fb70ad-5736-4f1c-9b78-3905d38f87c2">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="smmt-20220125.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i038cf3deceb14d27bdb232ec39ade856_D20220125-20220125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-25</xbrli:startDate><xbrli:endDate>2022-01-25</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i30b70720e7a840089df4218d50729d1e_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Washington, D.C. 20549</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">FORM <ix:nonNumeric contextRef="i038cf3deceb14d27bdb232ec39ade856_D20220125-20220125" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjMwYjcwNzIwZTdhODQwMDg5ZGY0MjE4ZDUwNzI5ZDFlL3NlYzozMGI3MDcyMGU3YTg0MDA4OWRmNDIxOGQ1MDcyOWQxZV8xL2ZyYWc6ZmI4NzExMWY1OGU1NGI5OWIyMjY1NTA3ZDBkMDVlNTAvdGV4dHJlZ2lvbjpmYjg3MTExZjU4ZTU0Yjk5YjIyNjU1MDdkMGQwNWU1MF8yMzgz_1ad34f4d-10d4-4e1e-8f1b-14db7ee2d6a6">8-K</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Date of Report (Date of Earliest Event Reported): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><ix:nonNumeric contextRef="i038cf3deceb14d27bdb232ec39ade856_D20220125-20220125" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjMwYjcwNzIwZTdhODQwMDg5ZGY0MjE4ZDUwNzI5ZDFlL3NlYzozMGI3MDcyMGU3YTg0MDA4OWRmNDIxOGQ1MDcyOWQxZV8xL2ZyYWc6ZmI4NzExMWY1OGU1NGI5OWIyMjY1NTA3ZDBkMDVlNTAvdGV4dHJlZ2lvbjpmYjg3MTExZjU4ZTU0Yjk5YjIyNjU1MDdkMGQwNWU1MF8yMjg_0268eea9-fac6-4998-9a56-a10e6e8798e7">January 25, 2022</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="padding-left:5.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i038cf3deceb14d27bdb232ec39ade856_D20220125-20220125" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjMwYjcwNzIwZTdhODQwMDg5ZGY0MjE4ZDUwNzI5ZDFlL3NlYzozMGI3MDcyMGU3YTg0MDA4OWRmNDIxOGQ1MDcyOWQxZV8xL2ZyYWc6ZmI4NzExMWY1OGU1NGI5OWIyMjY1NTA3ZDBkMDVlNTAvdGFibGU6ZTYwNjA4ZjNiMjBhNGIxY2E0YjVlMjFmNTI3YTYxOGQvdGFibGVyYW5nZTplNjA2MDhmM2IyMGE0YjFjYTRiNWUyMWY1MjdhNjE4ZF8wLTAtMS0xLTQ0Nzk0_38af3c50-0851-4663-94a2-db27e3ada334">Summit Therapeutics Inc.</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(Exact Name of Registrant as Specified in Its Charter)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i038cf3deceb14d27bdb232ec39ade856_D20220125-20220125" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjMwYjcwNzIwZTdhODQwMDg5ZGY0MjE4ZDUwNzI5ZDFlL3NlYzozMGI3MDcyMGU3YTg0MDA4OWRmNDIxOGQ1MDcyOWQxZV8xL2ZyYWc6ZmI4NzExMWY1OGU1NGI5OWIyMjY1NTA3ZDBkMDVlNTAvdGFibGU6ZTYwNjA4ZjNiMjBhNGIxY2E0YjVlMjFmNTI3YTYxOGQvdGFibGVyYW5nZTplNjA2MDhmM2IyMGE0YjFjYTRiNWUyMWY1MjdhNjE4ZF8zLTAtMS0xLTQ0Nzk0_44849c66-0412-4c65-9f37-1218b062ae28">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i038cf3deceb14d27bdb232ec39ade856_D20220125-20220125" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMwYjcwNzIwZTdhODQwMDg5ZGY0MjE4ZDUwNzI5ZDFlL3NlYzozMGI3MDcyMGU3YTg0MDA4OWRmNDIxOGQ1MDcyOWQxZV8xL2ZyYWc6ZmI4NzExMWY1OGU1NGI5OWIyMjY1NTA3ZDBkMDVlNTAvdGFibGU6ZTYwNjA4ZjNiMjBhNGIxY2E0YjVlMjFmNTI3YTYxOGQvdGFibGVyYW5nZTplNjA2MDhmM2IyMGE0YjFjYTRiNWUyMWY1MjdhNjE4ZF8zLTEtMS0xLTQ0Nzk0_317d0489-993c-4926-8519-430042aa2922">001-36866</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i038cf3deceb14d27bdb232ec39ade856_D20220125-20220125" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMwYjcwNzIwZTdhODQwMDg5ZGY0MjE4ZDUwNzI5ZDFlL3NlYzozMGI3MDcyMGU3YTg0MDA4OWRmNDIxOGQ1MDcyOWQxZV8xL2ZyYWc6ZmI4NzExMWY1OGU1NGI5OWIyMjY1NTA3ZDBkMDVlNTAvdGFibGU6ZTYwNjA4ZjNiMjBhNGIxY2E0YjVlMjFmNTI3YTYxOGQvdGFibGVyYW5nZTplNjA2MDhmM2IyMGE0YjFjYTRiNWUyMWY1MjdhNjE4ZF8zLTItMS0xLTQ0Nzk0_558adb48-a6ee-49fe-9b23-3478b8d6466d">37-1979717</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(State or Other Jurisdiction<br/>of Incorporation)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(Commission<br/>File Number)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(IRS Employer<br/>Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i038cf3deceb14d27bdb232ec39ade856_D20220125-20220125" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjMwYjcwNzIwZTdhODQwMDg5ZGY0MjE4ZDUwNzI5ZDFlL3NlYzozMGI3MDcyMGU3YTg0MDA4OWRmNDIxOGQ1MDcyOWQxZV8xL2ZyYWc6ZmI4NzExMWY1OGU1NGI5OWIyMjY1NTA3ZDBkMDVlNTAvdGFibGU6ZTYwNjA4ZjNiMjBhNGIxY2E0YjVlMjFmNTI3YTYxOGQvdGFibGVyYW5nZTplNjA2MDhmM2IyMGE0YjFjYTRiNWUyMWY1MjdhNjE4ZF82LTAtMS0xLTQ0Nzk0L3RleHRyZWdpb246ZTFkN2FlNGNhMDU1NDNiMmEzZGYyZjgxNTI4MmM1ZjNfNQ_42f642d0-a6b8-4537-a580-df0555fe9f34">One Broadway, 14th&#160;Floor</ix:nonNumeric>, <ix:nonNumeric contextRef="i038cf3deceb14d27bdb232ec39ade856_D20220125-20220125" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjMwYjcwNzIwZTdhODQwMDg5ZGY0MjE4ZDUwNzI5ZDFlL3NlYzozMGI3MDcyMGU3YTg0MDA4OWRmNDIxOGQ1MDcyOWQxZV8xL2ZyYWc6ZmI4NzExMWY1OGU1NGI5OWIyMjY1NTA3ZDBkMDVlNTAvdGFibGU6ZTYwNjA4ZjNiMjBhNGIxY2E0YjVlMjFmNTI3YTYxOGQvdGFibGVyYW5nZTplNjA2MDhmM2IyMGE0YjFjYTRiNWUyMWY1MjdhNjE4ZF82LTAtMS0xLTQ0Nzk0L3RleHRyZWdpb246ZTFkN2FlNGNhMDU1NDNiMmEzZGYyZjgxNTI4MmM1ZjNfOQ_71863030-8284-4806-bd83-58a0d8016269">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="i038cf3deceb14d27bdb232ec39ade856_D20220125-20220125" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjMwYjcwNzIwZTdhODQwMDg5ZGY0MjE4ZDUwNzI5ZDFlL3NlYzozMGI3MDcyMGU3YTg0MDA4OWRmNDIxOGQ1MDcyOWQxZV8xL2ZyYWc6ZmI4NzExMWY1OGU1NGI5OWIyMjY1NTA3ZDBkMDVlNTAvdGFibGU6ZTYwNjA4ZjNiMjBhNGIxY2E0YjVlMjFmNTI3YTYxOGQvdGFibGVyYW5nZTplNjA2MDhmM2IyMGE0YjFjYTRiNWUyMWY1MjdhNjE4ZF82LTAtMS0xLTQ0Nzk0L3RleHRyZWdpb246ZTFkN2FlNGNhMDU1NDNiMmEzZGYyZjgxNTI4MmM1ZjNfMTM_3656ea7e-5063-4404-b121-67e4bfcb2bb1">MA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i038cf3deceb14d27bdb232ec39ade856_D20220125-20220125" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjMwYjcwNzIwZTdhODQwMDg5ZGY0MjE4ZDUwNzI5ZDFlL3NlYzozMGI3MDcyMGU3YTg0MDA4OWRmNDIxOGQ1MDcyOWQxZV8xL2ZyYWc6ZmI4NzExMWY1OGU1NGI5OWIyMjY1NTA3ZDBkMDVlNTAvdGFibGU6ZTYwNjA4ZjNiMjBhNGIxY2E0YjVlMjFmNTI3YTYxOGQvdGFibGVyYW5nZTplNjA2MDhmM2IyMGE0YjFjYTRiNWUyMWY1MjdhNjE4ZF82LTItMS0xLTQ0Nzk0_84e2ed2a-f0ed-438a-8bb5-4f27200b1aa9">02142</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(Zip Code)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Registrant&#8217;s Telephone Number, Including Area Code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><ix:nonNumeric contextRef="i038cf3deceb14d27bdb232ec39ade856_D20220125-20220125" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjMwYjcwNzIwZTdhODQwMDg5ZGY0MjE4ZDUwNzI5ZDFlL3NlYzozMGI3MDcyMGU3YTg0MDA4OWRmNDIxOGQ1MDcyOWQxZV8xL2ZyYWc6ZmI4NzExMWY1OGU1NGI5OWIyMjY1NTA3ZDBkMDVlNTAvdGV4dHJlZ2lvbjpmYjg3MTExZjU4ZTU0Yjk5YjIyNjU1MDdkMGQwNWU1MF8yODk_3c4cfd4f-1027-4280-9238-0b0015ee2dfe">617</ix:nonNumeric>-<ix:nonNumeric contextRef="i038cf3deceb14d27bdb232ec39ade856_D20220125-20220125" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMwYjcwNzIwZTdhODQwMDg5ZGY0MjE4ZDUwNzI5ZDFlL3NlYzozMGI3MDcyMGU3YTg0MDA4OWRmNDIxOGQ1MDcyOWQxZV8xL2ZyYWc6ZmI4NzExMWY1OGU1NGI5OWIyMjY1NTA3ZDBkMDVlNTAvdGV4dHJlZ2lvbjpmYjg3MTExZjU4ZTU0Yjk5YjIyNjU1MDdkMGQwNWU1MF8yMzc3_13641a08-943b-48cc-956f-4f06c039d564">514-7149</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="padding-left:5.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Not Applicable</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(Former Name or Former Address, If Changed Since Last Report)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> General Instruction A.2. below):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i038cf3deceb14d27bdb232ec39ade856_D20220125-20220125" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjMwYjcwNzIwZTdhODQwMDg5ZGY0MjE4ZDUwNzI5ZDFlL3NlYzozMGI3MDcyMGU3YTg0MDA4OWRmNDIxOGQ1MDcyOWQxZV8xL2ZyYWc6ZmI4NzExMWY1OGU1NGI5OWIyMjY1NTA3ZDBkMDVlNTAvdGV4dHJlZ2lvbjpmYjg3MTExZjU4ZTU0Yjk5YjIyNjU1MDdkMGQwNWU1MF8yMzc4_1515426c-7a90-4a87-9a0d-deedb4ad609f">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i038cf3deceb14d27bdb232ec39ade856_D20220125-20220125" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjMwYjcwNzIwZTdhODQwMDg5ZGY0MjE4ZDUwNzI5ZDFlL3NlYzozMGI3MDcyMGU3YTg0MDA4OWRmNDIxOGQ1MDcyOWQxZV8xL2ZyYWc6ZmI4NzExMWY1OGU1NGI5OWIyMjY1NTA3ZDBkMDVlNTAvdGV4dHJlZ2lvbjpmYjg3MTExZjU4ZTU0Yjk5YjIyNjU1MDdkMGQwNWU1MF8yMzc1_c4b2e7b3-d4d6-4352-8bc5-3bc00dc70c41">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i038cf3deceb14d27bdb232ec39ade856_D20220125-20220125" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjMwYjcwNzIwZTdhODQwMDg5ZGY0MjE4ZDUwNzI5ZDFlL3NlYzozMGI3MDcyMGU3YTg0MDA4OWRmNDIxOGQ1MDcyOWQxZV8xL2ZyYWc6ZmI4NzExMWY1OGU1NGI5OWIyMjY1NTA3ZDBkMDVlNTAvdGV4dHJlZ2lvbjpmYjg3MTExZjU4ZTU0Yjk5YjIyNjU1MDdkMGQwNWU1MF8yMzgw_03816189-1564-4629-b57f-2e1af09f89a6">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i038cf3deceb14d27bdb232ec39ade856_D20220125-20220125" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjMwYjcwNzIwZTdhODQwMDg5ZGY0MjE4ZDUwNzI5ZDFlL3NlYzozMGI3MDcyMGU3YTg0MDA4OWRmNDIxOGQ1MDcyOWQxZV8xL2ZyYWc6ZmI4NzExMWY1OGU1NGI5OWIyMjY1NTA3ZDBkMDVlNTAvdGV4dHJlZ2lvbjpmYjg3MTExZjU4ZTU0Yjk5YjIyNjU1MDdkMGQwNWU1MF8yMzgy_bbff9edb-20c1-4b04-89a0-04cdf677ffdb">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))&#160;</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:6.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Title of Each Class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i038cf3deceb14d27bdb232ec39ade856_D20220125-20220125" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjMwYjcwNzIwZTdhODQwMDg5ZGY0MjE4ZDUwNzI5ZDFlL3NlYzozMGI3MDcyMGU3YTg0MDA4OWRmNDIxOGQ1MDcyOWQxZV8xL2ZyYWc6ZmI4NzExMWY1OGU1NGI5OWIyMjY1NTA3ZDBkMDVlNTAvdGFibGU6ZTIyNzA3MGMzZmZjNDhhOGEyM2Y5MzcwOTNhZDBjZmQvdGFibGVyYW5nZTplMjI3MDcwYzNmZmM0OGE4YTIzZjkzNzA5M2FkMGNmZF8xLTAtMS0xLTQ0Nzk0_f19274d1-b00b-4816-befd-4ef6f14cd555">Common stock, $0.01&#160;par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i038cf3deceb14d27bdb232ec39ade856_D20220125-20220125" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjMwYjcwNzIwZTdhODQwMDg5ZGY0MjE4ZDUwNzI5ZDFlL3NlYzozMGI3MDcyMGU3YTg0MDA4OWRmNDIxOGQ1MDcyOWQxZV8xL2ZyYWc6ZmI4NzExMWY1OGU1NGI5OWIyMjY1NTA3ZDBkMDVlNTAvdGFibGU6ZTIyNzA3MGMzZmZjNDhhOGEyM2Y5MzcwOTNhZDBjZmQvdGFibGVyYW5nZTplMjI3MDcwYzNmZmM0OGE4YTIzZjkzNzA5M2FkMGNmZF8xLTEtMS0xLTQ0Nzk0_2fb290a9-d773-43a6-8f7b-27940e99abb0">SMMT</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i038cf3deceb14d27bdb232ec39ade856_D20220125-20220125" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjMwYjcwNzIwZTdhODQwMDg5ZGY0MjE4ZDUwNzI5ZDFlL3NlYzozMGI3MDcyMGU3YTg0MDA4OWRmNDIxOGQ1MDcyOWQxZV8xL2ZyYWc6ZmI4NzExMWY1OGU1NGI5OWIyMjY1NTA3ZDBkMDVlNTAvdGFibGU6ZTIyNzA3MGMzZmZjNDhhOGEyM2Y5MzcwOTNhZDBjZmQvdGFibGVyYW5nZTplMjI3MDcwYzNmZmM0OGE4YTIzZjkzNzA5M2FkMGNmZF8xLTItMS0xLTQ0Nzk0_16d7802a-2aba-4edc-a5d5-bc65a4daf5ca">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Emerging growth company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i038cf3deceb14d27bdb232ec39ade856_D20220125-20220125" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjMwYjcwNzIwZTdhODQwMDg5ZGY0MjE4ZDUwNzI5ZDFlL3NlYzozMGI3MDcyMGU3YTg0MDA4OWRmNDIxOGQ1MDcyOWQxZV8xL2ZyYWc6ZmI4NzExMWY1OGU1NGI5OWIyMjY1NTA3ZDBkMDVlNTAvdGV4dHJlZ2lvbjpmYjg3MTExZjU4ZTU0Yjk5YjIyNjU1MDdkMGQwNWU1MF8yMzc2_bcfdf7fb-a2eb-48d0-99f6-3b1be8680048">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#9744;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.717%"><tr><td style="width:1.0%"></td><td style="width:30.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.322%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 8.01</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Other Events.</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 25, 2022, Summit Therapeutics Inc. (the &#8220;Company&#8221;) issued a press release announcing the approval of the Board of Directors of the Company (the &#8220;Board&#8221;) of a rights offering to its stockholders of record as of the close of business on February 4, 2022. The rights offering will be made through the distribution of non-transferable subscription rights to purchase shares of the Company&#8217;s common stock, par value $0.01 (the &#8220;Common Stock&#8221;), at a price per share equal to the lesser of (i) $2.06 per share, the closing price of the Common Stock on January 21, 2022 or (ii) the volume weighted average price of the Common Stock for the ten consecutive trading days through and including the expiration date of the offering.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The rights offering will include an over-subscription right to permit each rights holder that exercises its basic subscription rights in full to purchase additional shares of Common Stock that remain unsubscribed at the expiration of the offering. The availability of the over-subscription right will be subject to certain terms and conditions to be set forth in the offering documents.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Robert W. Duggan, the Company&#8217;s Chairman of the Board and Chief Executive Officer, and the beneficial owner of approximately 70% of the Company&#8217;s issued and outstanding Common Stock prior to this rights offering, and Dr. Maky Zanganeh, the Company&#8217;s Chief Operating Officer, a member of the Board, and the beneficial owner of approximately 6.5% of the Company&#8217;s issued and outstanding Common Stock prior to this rights offering, have each indicated that they intend to participate in the rights offering, but have not indicated a minimum level of participation or made any formal binding commitment to participate.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Assuming that the rights offering is fully subscribed, the Company expects to receive gross proceeds of up to $100 million, less expenses related to the rights offering.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A copy of the press release related to the matters set forth herein is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.717%"><tr><td style="width:1.0%"></td><td style="width:30.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.322%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 9.01</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Financial Statements and Exhibits.</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d) Exhibits</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.945%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3pt;padding-right:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Exhibit Number</span></div></td><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.02pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="a2022_prx0125xannouncement.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.02pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="a2022_prx0125xannouncement.htm">Press release, dated January 25, 2022</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104</span></td><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURES</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="padding-left:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="6" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SUMMIT THERAPEUTICS&#160;INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="6" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="6" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: January 25, 2022</span></td><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Robert W. Duggan</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer and Executive Chairman; Principal Executive Officer and Principal Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "smmt-20220125.htm", "description": "8-K", "secsgml_size_bytes": 40213}]
{"company-data": {"conformed-name": "Summit Therapeutics Inc.", "cik": "0001599298", "assigned-sic": "2834", "irs-number": "000000000", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-36866", "film-number": "22554757"}, "business-address": {"street1": "ONE BROADWAY", "street2": "14TH FLOOR", "city": "CAMBRIDGE", "state": "MA", "zip": "02142", "phone": "617-514-7149"}, "mail-address": {"street1": "ONE BROADWAY", "street2": "14TH FLOOR", "city": "CAMBRIDGE", "state": "MA", "zip": "02142"}, "former-company": [{"former-conformed-name": "Summit Therapeutics plc", "date-changed": "20150219"}, {"former-conformed-name": "Summit Corp plc", "date-changed": "20140205"}]}
smmt-20220125
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
January 25, 2022
Summit Therapeutics Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
001-36866
37-1979717
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
One Broadway, 14th Floor
,
Cambridge
,
MA
02142
(Address of Principal Executive Offices)
(Zip Code)
Registrant's Telephone Number, Including Area Code:
617
-
514-7149
Not Applicable
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on Which Registered
Common stock, $0.01 par value per share
SMMT
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 8.01
Other Events.
On January 25, 2022, Summit Therapeutics Inc. (the "Company") issued a press release announcing the approval of the Board of Directors of the Company (the "Board") of a rights offering to its stockholders of record as of the close of business on February 4, 2022. The rights offering will be made through the distribution of non-transferable subscription rights to purchase shares of the Company's common stock, par value $0.01 (the "Common Stock"), at a price per share equal to the lesser of (i) $2.06 per share, the closing price of the Common Stock on January 21, 2022 or (ii) the volume weighted average price of the Common Stock for the ten consecutive trading days through and including the expiration date of the offering.
The rights offering will include an over-subscription right to permit each rights holder that exercises its basic subscription rights in full to purchase additional shares of Common Stock that remain unsubscribed at the expiration of the offering. The availability of the over-subscription right will be subject to certain terms and conditions to be set forth in the offering documents.
Robert W. Duggan, the Company's Chairman of the Board and Chief Executive Officer, and the beneficial owner of approximately 70% of the Company's issued and outstanding Common Stock prior to this rights offering, and Dr. Maky Zanganeh, the Company's Chief Operating Officer, a member of the Board, and the beneficial owner of approximately 6.5% of the Company's issued and outstanding Common Stock prior to this rights offering, have each indicated that they intend to participate in the rights offering, but have not indicated a minimum level of participation or made any formal binding commitment to participate.
Assuming that the rights offering is fully subscribed, the Company expects to receive gross proceeds of up to $100 million, less expenses related to the rights offering.
A copy of the press release related to the matters set forth herein is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number
Description
99.1
Press release, dated January 25, 2022
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SUMMIT THERAPEUTICS INC.
Date: January 25, 2022
By:
/s/ Robert W. Duggan
Chief Executive Officer and Executive Chairman; Principal Executive Officer and Principal Financial Officer